Brand Name Drug Executives Should Commit to Affordable Pricing on COVID-19… Read More
Part IV: Escalating Assault on 340B Program for Providers Serving America’s… Read More
Part III: Angling to Price-Gouge American Public on COVID-19 Treatments… Read More
Part II: Gaming the System to Undermine Competition at the Expense of American… Read More
Part I: Sticking with Price-Hiking “Business-as-Usual” During Pandemic… Read More
Brand Name Drug Companies Must be Held Accountable for Pandemic Price Hikes… Read More
Misguided Measure Would Increase Medicare Part D Premiums, Cost Taxpayers More… Read More
Drug Companies Target PBMs and Rebates That Play a Critical Role in Lowering… Read More
Little Surprise Big Pharma Bailout That Would Hike Medicare Premiums Was A… Read More
AMERICAN VOTERS OVERWHELMINGLY SUPPORT MARKET-BASED SOLUTIONS TO HOLD DRUG… Read More
Policymakers Should Focus On Market-Based Solutions To Hold Drug Companies… Read More
Drug Companies’ Focus on Most Profitable Treatments Hampers Pandemic… Read More